FDA Thwarts Leo Pharma's US Launch Plans For Tralokinumab
Agency Issues CRL For Atopic Dermatitis Drug
A week after getting the thumbs-up from the CHMP for tralokinumab, the Denmark-based dermatology specialist has been hit by a complete response letter from US regulators requesting more data about a device component of the IL-13 inhibitor.
You may also be interested in...
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.